Ernexa Therapeutics (ERNA) regained compliance with Nasdaq for continued listing and that its stock will continue to trade on The Nasdaq Stock Market. On July 1, 2025, the company received formal notice from Nasdaq stating that Ernexa has regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2) for continued listing.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERNA:
- Ernexa Therapeutics expands Scientific Advisory Board
- Ernexa secures $6M in second closing under securities purchase agreement
- Eterna Therapeutics Implements 1-for-15 Reverse Stock Split
- Eterna Therapeutics trading halted, news pending
- Ernexa Therapeutics files to sell 57.05M shares of common stock for holders